← Leaderboards
Nicholas M Adams
Bioventures, Inc.
$1,475,205
Attributed
$4,425,616
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2017–21$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,425,616 · 2
By mechanism
R42$2,845,149 · 1
R01$1,580,467 · 1
Top collaborators
- Frederick R Haselton7 shared
- Steven John Simmons3 shared
- Elliott Paul Dawson2 shared
- Jonathan E Schmitz2 shared
Most similar at Bioventures, Inc.
Same institution · by research overlap
- Steven John Simmons$559,942
- Elliott Paul Dawson$388,441
Others in their field
Other Emerging Leaders on “Performance”
- Leonard Freedman · Leidos Biomedical Research, Inc.$272,749,741
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Kimberly Smith · Ppd Development Lp$115,671,664
- Lynn Briscoe · Leidos Biomedical Research, Inc.$105,069,915
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Leonard Freedmand · Leidos Biomedical Research, Inc.$63,100,245
Research focus
PerformanceResourcesInstrumentOpticsPreparationReagentDiagnosticImageMolecular DiagnosisOfficesPhysicians&AposPoint Of CareReactionClia CertifiedClinicBaseDesignGoldInstrumentationLaboratoriesMolecular DiagnosticsMonitorEnantiomerSampling
Grant awards (7)
Point-of-Care RT-PCR System to Inform COVID-19 and Respiratory Illness Decisions$788,805
R01 · FY2021 · AI
Point-of-Care RT-PCR System to Inform COVID-19 and Respiratory Illness Decisions$791,662
R01 · FY2020 · AI
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$398,573
R42 · FY2019 · HG
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$886,669
R42 · FY2018 · HG
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$394,585
R42 · FY2018 · HG
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$878,071
R42 · FY2017 · HG
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents$287,251
R42 · FY2017 · HG